CA3254091A1 - Compositions of and methods for in vitro viral genome engineering - Google Patents

Compositions of and methods for in vitro viral genome engineering

Info

Publication number
CA3254091A1
CA3254091A1 CA3254091A CA3254091A CA3254091A1 CA 3254091 A1 CA3254091 A1 CA 3254091A1 CA 3254091 A CA3254091 A CA 3254091A CA 3254091 A CA3254091 A CA 3254091A CA 3254091 A1 CA3254091 A1 CA 3254091A1
Authority
CA
Canada
Prior art keywords
compositions
methods
viral genome
genome engineering
vitro viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3254091A
Other languages
English (en)
Inventor
Kyle C. Cady
E. Magda Barbu
Christen Dipetrillo
Original Assignee
C3J Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C3J Therapeutics Inc filed Critical C3J Therapeutics Inc
Publication of CA3254091A1 publication Critical patent/CA3254091A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
CA3254091A 2014-12-16 2015-12-15 Compositions of and methods for in vitro viral genome engineering Pending CA3254091A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201462092707P 2014-12-16 2014-12-16
US62/092,707 2014-12-16
US201562102362P 2015-01-12 2015-01-12
US62/102,362 2015-01-12
US201562242811P 2015-10-16 2015-10-16
US62/242,811 2015-10-16

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2971205A Division CA2971205A1 (en) 2014-12-16 2015-12-15 Compositions of and methods for in vitro viral genome engineering

Publications (1)

Publication Number Publication Date
CA3254091A1 true CA3254091A1 (en) 2025-10-27

Family

ID=56127485

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2971205A Pending CA2971205A1 (en) 2014-12-16 2015-12-15 Compositions of and methods for in vitro viral genome engineering
CA3254091A Pending CA3254091A1 (en) 2014-12-16 2015-12-15 Compositions of and methods for in vitro viral genome engineering

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2971205A Pending CA2971205A1 (en) 2014-12-16 2015-12-15 Compositions of and methods for in vitro viral genome engineering

Country Status (9)

Country Link
US (4) US10221398B2 (https=)
EP (2) EP3234136B1 (https=)
JP (2) JP6842417B2 (https=)
CN (2) CN113215115B (https=)
AU (2) AU2015362618B2 (https=)
CA (2) CA2971205A1 (https=)
EA (1) EA038595B1 (https=)
ES (1) ES2991077T3 (https=)
WO (1) WO2016100389A1 (https=)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5548121B2 (ja) 2007-05-14 2014-07-16 リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク バイオフィルム中の細菌細胞における生理学的分散応答の誘導
US10323236B2 (en) 2011-07-22 2019-06-18 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
ES2781323T3 (es) 2014-06-23 2020-09-01 Regeneron Pharma Montaje de ADN mediado por nucleasas
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
CN113215115B (zh) 2014-12-16 2024-07-02 C3J治疗公司 用于体外病毒基因组工程的组合物和方法
US20160362667A1 (en) * 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
US10513732B2 (en) * 2015-07-13 2019-12-24 New York University Sequencing methods and kits
IL310721B2 (en) 2015-10-23 2025-11-01 Harvard College Nucleobase editors and uses thereof
US11433260B2 (en) 2015-12-21 2022-09-06 Gholam A. Peyman Cancer treatment methods using thermotherapy and/or enhanced immunotherapy
US10136820B2 (en) * 2015-12-21 2018-11-27 Gholam A. Peyman Method to visualize very early stage neoplasm or other lesions
WO2017172645A2 (en) * 2016-03-28 2017-10-05 The Charles Stark Draper Laboratory, Inc. Bacteriophage engineering methods
CN110214183A (zh) 2016-08-03 2019-09-06 哈佛大学的校长及成员们 腺苷核碱基编辑器及其用途
WO2018031683A1 (en) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Programmable cas9-recombinase fusion proteins and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
DK3503915T5 (da) 2016-08-26 2024-09-02 Telesis Bio Inc Genetisk modificerede Vibro natriegen
KR102622411B1 (ko) 2016-10-14 2024-01-10 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018071841A1 (en) * 2016-10-14 2018-04-19 The Forsyth Institute Compositions and methods for evading bacterial defense mechanisms
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
WO2018148410A1 (en) * 2017-02-09 2018-08-16 The Charles Stark Draper Laboratory Inc. Bacteriophage recombination followed by blockage of nonrecombinant bacteriophage replication
EP3592846A1 (en) 2017-03-06 2020-01-15 Massachusetts Institute of Technology Methods of cloning prophages and producing lytic phage particles
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US12390514B2 (en) 2017-03-09 2025-08-19 President And Fellows Of Harvard College Cancer vaccine
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11535843B2 (en) 2017-06-01 2022-12-27 The Charles Stark Draper Laboratory, Inc. Phage engineering: protection by circularized intermediate
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US10174295B1 (en) * 2017-08-01 2019-01-08 The Charles Stark Draper Laboratory, Inc. Composition of matter: engineering of Escherichia coli phage K1E
US11891630B2 (en) 2017-08-08 2024-02-06 The Charles Stark Draper Laboratory, Inc. Bacteriophage engineering via semi-synthesis
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
KR20250107288A (ko) 2017-10-16 2025-07-11 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
JP6923862B2 (ja) * 2018-05-22 2021-08-25 学校法人自治医科大学 抗菌ファージ、治療用組成物、殺菌剤、食品、細菌判別キット、治療用組成物製造方法、細菌除去方法、細菌判別方法、及び動物治療方法
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020092748A1 (en) * 2018-11-01 2020-05-07 The Trustees Of Princeton University System for protein inactivation and recombinant phages for targeted bacterial killing, infection, biodetection, and as a means of protein extraction
WO2020109339A1 (en) * 2018-11-27 2020-06-04 Eligo Bioscience Chimeric receptor binding proteins for use in bacterial delivery vehicles
KR20210107053A (ko) * 2018-12-21 2021-08-31 엘리고 바이오사이언스 박테리아 전달 비히클에서 사용을 위한 분지형 수용체 결합 다수-서브유닛 단백질 복합체
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CA3128507A1 (en) 2019-02-06 2020-08-13 Fred Hutchinson Cancer Research Center Minicircle producing bacteria engineered to differentially methylate nucleic acid molecules therein
WO2020191233A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
RU2771374C1 (ru) 2019-04-04 2022-05-04 Редженерон Фармасьютикалс, Инк. Способы для бесшовного внесения целевых модификаций в направленные векторы
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
IL297761A (en) 2020-05-08 2022-12-01 Broad Inst Inc Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence
CN114540389B (zh) * 2020-11-26 2024-05-14 深圳华大生命科学研究院 一种制备基因工程病毒的方法及其应用
CN112778399A (zh) * 2021-01-21 2021-05-11 南开大学 一类源自毒性淀粉样纤维纳米抗菌肽的制备及性质表征方法
JP2022117439A (ja) * 2021-01-29 2022-08-10 学校法人立教学院 インビトロパッケージングを用いた多断片ｄｎａの連結および細胞内導入方法
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (en) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
AU2022323171A1 (en) * 2021-08-02 2024-03-07 Armata Pharmaceuticals, Inc. Bacteriophages with improved antimicrobial activity
CN113755451B (zh) * 2021-09-03 2023-06-06 广西大学 一株大肠杆菌噬菌体gn6及其应用
EP4248987A1 (en) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Chimeric bacteriocins and method for the control of pseudomonas
JP2025516823A (ja) 2022-05-19 2025-05-30 ライエル・イミュノファーマ・インコーポレイテッド Ｎｒ４ａ３を標的とするポリヌクレオチド及びその使用
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025208072A1 (en) * 2024-03-29 2025-10-02 The General Hospital Corporation Methods and materials for treating disorders related to bacterial infections

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877279A (en) * 1994-10-13 1999-03-02 Nanoframes, Llc Materials for the production of nanometer structures and use thereof
EP1030861A4 (en) * 1997-10-31 2001-09-05 Maxygen Inc MODIFICATION OF VIRUSTROPISMIUS AND THE ECONOMIC SPECTRUM BY VIRAL GENOM MIXING
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB9809414D0 (en) * 1998-05-02 1998-07-01 Scottish Crop Research Inst Method
US7019122B1 (en) 1998-10-30 2006-03-28 Janssen Pharmaceutica N.V. Unusual retrotransposon from the yeast Candida albicans
ES2252263T3 (es) * 2000-07-25 2006-05-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Bacteriofago que tiene una gama de hospedadores multiple.
WO2006021944A1 (en) 2004-08-12 2006-03-02 Leanway Automatic Areanas Ltd. Enhanced database structure configuration
US8182804B1 (en) * 2004-09-13 2012-05-22 Trustees Of Boston University Engineered enzymatically active bacteriophages and methods of uses thereof
JP5136766B2 (ja) * 2004-12-15 2013-02-06 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラベクター
WO2007005053A1 (en) 2005-06-30 2007-01-11 Codon Devices, Inc. Hierarchical assembly methods for genome engineering
ATE474909T1 (de) 2005-12-29 2010-08-15 Abl Biotechnologies Ltd Neuer schizochytrium-limacinum-stamm, der sich für die produktion von lipiden und extrazellulären polysacchariden eignet, sowie verfahren hierfür
WO2008027472A2 (en) 2006-08-29 2008-03-06 Danisco Us, Inc., Genencor Division Compositions and methods for improved protein production
WO2008141757A1 (en) 2007-05-23 2008-11-27 Cognis Ip Management Gmbh Efficient astaxanthin production strains derived from haematococcus pluvialis
GB0715416D0 (en) 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage
JP2011518543A (ja) * 2008-01-10 2011-06-30 トラスティーズ オブ ボストン ユニバーシティ 抗微生物剤のための佐剤としての改変バクテリオファージならびにその組成物および使用方法
AU2009214435C1 (en) 2008-02-15 2014-07-17 Synthetic Genomics, Inc. Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
CN101928670B (zh) 2009-09-24 2012-02-22 上海天伟生物制药有限公司 一种抗生素的高产菌株及其制备方法和用途
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
SG188566A1 (en) 2010-09-17 2013-04-30 Tecnifar Ind Tecnica Farmaceutica S A Antibacterial phage, phage peptides and methods of use thereof
EP3597764A3 (en) * 2012-02-01 2020-05-06 SGI-DNA, Inc. Material and methods for the synthesis of error-minimized nucleic acid molecules
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2015035168A1 (en) * 2013-09-05 2015-03-12 Massachusetts Institute Of Technolgy Tuning bacteriophage host range
JP2017537650A (ja) * 2014-10-09 2017-12-21 ライポテック・ピーティーワイ・リミテッド キメラタンパク質
CN113215115B (zh) 2014-12-16 2024-07-02 C3J治疗公司 用于体外病毒基因组工程的组合物和方法

Also Published As

Publication number Publication date
JP7133671B2 (ja) 2022-09-08
ES2991077T3 (es) 2024-12-02
EP3234136A4 (en) 2018-10-10
AU2022202713B2 (en) 2025-01-02
JP2017537643A (ja) 2017-12-21
JP6842417B2 (ja) 2021-03-17
EA038595B1 (ru) 2021-09-21
CN113215115B (zh) 2024-07-02
US20160186147A1 (en) 2016-06-30
CN107278227B (zh) 2021-05-28
JP2021074024A (ja) 2021-05-20
US20210087538A1 (en) 2021-03-25
EP3234136B1 (en) 2024-08-21
US10221398B2 (en) 2019-03-05
WO2016100389A1 (en) 2016-06-23
US20190211312A1 (en) 2019-07-11
AU2015362618B2 (en) 2022-01-27
EP4484556A2 (en) 2025-01-01
EA201791343A1 (ru) 2018-03-30
EP4484556A3 (en) 2025-05-07
EP3234136A1 (en) 2017-10-25
US10711253B2 (en) 2020-07-14
CA2971205A1 (en) 2016-06-23
AU2015362618A1 (en) 2017-07-13
US20190322988A1 (en) 2019-10-24
AU2022202713A1 (en) 2022-05-19
US10837004B2 (en) 2020-11-17
CN107278227A (zh) 2017-10-20
US11913032B2 (en) 2024-02-27
CN113215115A (zh) 2021-08-06
HK1245838A1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
CA3254091A1 (en) Compositions of and methods for in vitro viral genome engineering
IL320861B1 (en) Preparations and methods for internalizing enzymes
IL287586A (en) Methods and preparations for enriching breeding products
ZA201801578B (en) Methods and compositions for marker-free genome modification
EP3183367A4 (en) Compositions and methods for enrichment of nucleic acids
IL247309A0 (en) Preparations for inhibiting virus replication and methods for their preparation and use
EP3080274A4 (en) Methods and compositions for genome engineering
EP3094720A4 (en) Compositions and methods of preparing airway cells
EP3240889A4 (en) Compositions and methods for high efficiency in vivo genome editing
EP3152319A4 (en) Methods and compositions for nuclease design
EP3058072A4 (en) Delivery methods and compositions for nuclease-mediated genome engineering
EP3256140A4 (en) Methods and compositions for ebola virus vaccination
EP3215602A4 (en) Methods and materials for producing recombinant viruses in eukaryotic microalgae
EP3105327A4 (en) Compositions and methods of using microrna inhibitors
IL259894A (en) Improved compositions and improved methods for viral delivery of neoepitopes and their use
EP3190886A4 (en) Compositions and methods of use thereof
EP3204426A4 (en) Compositions and methods for treating viral hemorrhagic fever
EP3250553A4 (en) Compositions and methods for inhibiting viral infection
EP3110422A4 (en) Compositions and methods for the delivery of therapeutics
EP3250550A4 (en) Compositions and methods for viral sensitization
EP3227318A4 (en) Dpp4 immunoadhesin compositions and methods
EP3113774A4 (en) Compositions of grapiprant and methods for using the same
EP3256608A4 (en) RNA CONTAINING COMPOSITIONS AND METHODS OF USE
EP3207029A4 (en) Tryptamide compositions and methods of use
EP3091996A4 (en) Compositions and methods for in vitro assays of fibrin activity

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20240905

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20240905

D16 Fast track examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D16-D108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION REQUESTED - PPH

Effective date: 20240905

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250207

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250324

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250324

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250402

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250512

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250513

D17 Fast track examination accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D17-D112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ADVANCED EXAMINATION DETERMINED COMPLIANT - PPH

Effective date: 20250612

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20251027

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20251203

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20251203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251212

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251212

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260309

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260323